Guanyu Ruan

Guanyu Ruan

Auto-generated profile, based on publicly available information

Guanyu Ruan

Fujian Clinical Research Center for Gynecological Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
PSPengming Sun
Pengming Sun
YSYiyi Song
Yiyi Song
GRGuanyu Ruan
Guanyu Ruan
XMXiaodan Mao
Xiaodan Mao
YKYafang Kang
Yafang Kang
FLFen Lin
Fen Lin
Sun P, et al. J Gynecol Oncol. 2017 Mar;28(5):e50. https://doi.org/10.3802/jgo.2017.28.e50

1 October 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
BDBinhua Dong
Binhua Dong
PSPengming Sun
Pengming Sun
GRGuanyu Ruan
Guanyu Ruan
WHWeiyi Huang
Weiyi Huang
XMXiaodan Mao
Xiaodan Mao
FLFen Lin
Fen Lin
Purpose: Currently, the associations between type-specific high-risk human papillomavirus (HR-HPV) viral loads and cervical lesions are still inconsistent. We aimed to assess the type-specific HR-HPV viral load as a risk triage indicator for development of high-grade squamous intraepithelial lesion or worse (≥HSIL). Patients and methods: A total of 19,446 women who underwent primary screening for cervical cancer using Cervista® HR-HPV and cytology assays were enrolled. The viral loads of 1,396 HR-HPV-positive specimens confirmed by Cervista® assay were detected by BioPerfectus Multiplex Real-Time PCR assay. The correlation between viral loads and cervical lesions was analyzed. The optimal cutoffs of individual HR-HPV viral loads used to predict ≥HSIL were determined from the receiver operating characteristic curve. A logistic regression model was used to analyze the relationship between covariates and the probability of ≥HSIL. Results: The viral loads of HPV-16, -31, -33, -52, and -58 were positively correlated with the severity of the cervical lesion, which was significantly elevated in patients with ≥HSIL, whereas those of HPV-18, -45, -56, -59, and other types were not. The optimal cutoffs of the log10-transformed viral loads for HPV-16, -31, -33, -52, and -58 in identifying ≥HSIL were 4.26, 4.46, 4.48, 4.36, and 4.26 copies per 10,000 cells, respectively. Furthermore, multivariate analysis indicated that type-specific viral loads of HPV-16, -31, -33, -52, and -58 exceeding the cutoffs could be independent risk factors for the incidence of ≥HSIL. Conclusion: The BioPerfectus Multiplex Real-Time PCR viral load assay provides viable triage for ≥HSIL when using appropriate cutoff levels.

1 January 2018 in Cancer Control
Verified
Journal Article
Open access
PDF file
LCLihua Chen
Lihua Chen
YSYiyi Song
Yiyi Song
GRGuanyu Ruan
Guanyu Ruan
QZQiaoyu Zhang
Qiaoyu Zhang
FLFen Lin
Fen Lin
PSPengming Sun
Pengming Sun
The use of the human papillomavirus (HPV) vaccine was recently approved in Mainland China. This study determined the knowledge and attitudes of young women aged 20 to 35 years in Fujian Province, China, with regard to HPV and vaccination and explored the potential factors influencing their attitudes toward HPV vaccination. This was a cross-sectional study that collected data regarding the knowledge on and attitudes toward HPV and vaccination using questionnaires. Furthermore, the prevalence of HPV was determined from the sampled participants. A total of 1001 young women were included in the survey. This study demonstrated that the HPV prevalence rate was 15.7% (157/1001). Among all patients, 44.9% (n = 449) had heard of HPV; however, detailed knowledge about HPV was lacking. The majority (83.7%) expressed a willingness to be vaccinated. Specifically, knowledge of the dangers of HPV infection was significantly associated with the willingness to be vaccinated. In this study, women cited some concerns and expressed high expectations for the HPV vaccine, but the costs of vaccination reduced their willingness to be vaccinated. This study found that most patients did not have a detailed knowledge of HPV. Thus, there is a need for continued HPV promotion and education efforts, especially on the dangers of HPV infection, among young women aged 20 to 35 years in Fujian Province, China. Furthermore, it is important to subsidize the costs of vaccination for promoting vaccination campaigns in China.

1 January 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
GRGuanyu Ruan
Guanyu Ruan
LYLixiang Ye
Lixiang Ye
GLGuifen Liu
Guifen Liu
JAJian An
Jian An
JSJalid Sehouli
Jalid Sehouli
PSPengming Sun
Pengming Sun
The impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains uncertain, which has been the focus of studies on the management of epithelial ovarian cancer (EOC). To investigate the efficacy of bevacizumab combinations with different regimens in the treatment of patients with EOC, a meta-analysis of Phase III randomized controlled trials was conducted. The databases searched included PubMed, Embase, ClinicalTrials.gov, Chinese Knowledge Infrastructure, as well as the Cochrane Central Register of Controlled Trials. After evaluation of quality, a meta-analysis of valid extracted data was performed using Review Manager (RevMan) software. Five studies with 4,369 patients were included. Bevacizumab plus chemotherapy improved progression-free survival (hazard ratio [HR] =0.63; 95% confidence interval [CI], 0.51–0.77; P<0.01) and overall survival (HR =0.91; 95% CI, 0.84–0.99; P<0.05). Interestingly, in patients with a high risk of progression, the subgroups that received bevacizumab combined with different regimens of chemotherapy showed a significant improvement with paclitaxel plus carboplatin-based chemotherapy (HR =0.86; 95% CI, 0.77–0.95; P0.05) in overall survival. The combination of bevacizumab and paclitaxel plus carboplatin-based regimens offers a new treatment option for women with EOC, especially in those with a high risk of progression.

1 August 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
PSPengming Sun
Pengming Sun
XMXiaodan Mao
Xiaodan Mao
MGMin Gao
Min Gao
MHMeiMei Huang
MeiMei Huang
LCLiLi Chen
LiLi Chen
JSJalid Sehouli
Jalid Sehouli
Purpose: To explore the targeted therapy of estrogen-related receptor α (ERRα) in endometrial cancer (EC) cells and its potential mechanisms. Methods: The mRNA and protein expression levels of ERRα and estrogen receptor α (ERα) were detected by qPCR and Western blotting in RL-952, AN3-CA, HEC-1A, and HEC-1B EC cell lines. After treatment with the ERRα-specific antagonist XCT790 or infection with lentivirus-mediated small interfering RNA (siRNA) targeting the ERRα (siRNA-ERRα), cell proliferation and apoptosis were evaluated by MTS assay and flow cytometry. After treatment with siRNA-ERRα, the expression profiles of transcription factors (TFs) were analyzed by protein/DNA arrays in EC cells. Results: The relative mRNA levels of ERRa in RL-952 (1±0.0831) and AN3-CA (1.162±0.0325) were significantly higher than those in HEC-1A (0.3081±0.0339) and HEC-1B (0.1119±0.0091) (P<0.05), and similar results were observed for ERRα protein levels. A higher ratio of ERa/ERRa was observed in ERα-positive RL-952 (10-fold) and ANC-3A (8.5-fold) cells, whereas a lower ratio was observed in ERα-negative HEC-1A (3.75-fold) and HEC-1B cells (0-fold). Both – exogenous XCT790 and endogenous siRNA-ERRa – can decrease the expression of ERRα, thereby inhibiting proliferation but promoting apoptosis in both ERα-positive and -negative EC cells. The XCT790 presented higher proliferation-inhibition and apoptosis rates in the ERα-positive than ERα-negative cells, whereas the siRNA-ERRα exhibited higher proliferation-inhibition and apoptosis rates in the ERα-negative than in ERα-positive cells. In total, 3 upregulated and 17 downregulated TFs were screened out by knocked-down expression of ERRα in all EC cells. Among them, the upregulated TFs organic cation transporter 3/4(Oct3/4), hepatic nuclear factor 4 (HNF4), HNF4 and chicken ovalbumin upstream TF (COUP-TF) as well as downregulated transcription factor EB (TFEB) were found to be statistically significant (P<0.05). Conclusion: Targeting ERRα provides a promising novel endocrine therapeutic strategy.

1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YKYafang Kang
Yafang Kang
PSPengming Sun
Pengming Sun
XMXiaodan Mao
Xiaodan Mao
BDBinhua Dong
Binhua Dong
GRGuanyu Ruan
Guanyu Ruan
LCLihua Chen
Lihua Chen
Kang Y, et al. J Gynecol Oncol. 2018 Nov;30(3):e29. https://doi.org/10.3802/jgo.2019.30.e29